Author archives

Rodica ANGHEL

Latest posts by Rodica ANGHEL (see all)

Articles signed on MÆDICA, JCM:

Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer

SELECT ISSUE


MÆDICA - a Journal of Clinical Medicine | Vol. 13, nr. 4, 2018
CNCSIS - CMR - B+ OBBCSSR

Members Area


Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer

, , and

ABSTRACT

The immune system is very critical in suppression of cancer development. The composition of breast cancer-infiltrating lymphocytes has been widely investigated so far and it is accepted that the presence of high tumor-infiltrating lymphocytes (TILs) is associated with improved prognoses. The correlation between various TIL subpopulations and experimentally observed responses is still characterized by a certain grade of controversy. Modulating the immune system is promising treatment strategy in breast cancer, particularly in HER2 positive and triple-negative molecular subtypes. However, there is still much to be done to implement immunotherapy in this disease.
Keywords: tumor-infiltrating lymphocytes, breast cancer, immunotherapy, HER2

Full text | PDF

Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 10, nr. 4, 2015 CNCSIS - CMR - B+ OBBCSSR

Members Area


Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine

and

ABSTRACT

Angiogenesis plays a major role in tumor growth and metastatic spread of cancer, and therefore inhibition of angiogenesis seems a promising therapeutic strategy. In order to grow beyond microscopic size, tumors need a better delivery of nutrients and oxygen so neovascularization must occur. Vascular endothelial growth factor [VEGF] pathway is the most important factor in promoting angiogenesis. This pathway may be blocked by either extracellular interference with VEGF itself (bevacizumab [BEV] or aflibercept), or intracytoplasmic inhibition of VEGF receptor (pazopanib, nintedanib, cediranib, sunitinib and sorafenib). Approximately 97% of ovarian tumors over express the VEGF ligand and this is correlated with early metastases, ascites formation and poor prognosis. The addition of antiangiogenic agents to standard chemotherapy in ovarian cancer is a rational therapeutic option for primary or recurrent ovarian carcinoma but it does not represent a new standard treatment until the subset of patients who benefit the most is identified.

Keywords: angiogenesis, VEGF, ovarian cancer

Full text | PDF